CMS is famous for not being able to negotiate prices – and its payment for physician-administered drugs notoriously incentivizes higher prices. Yet, as the Biogen/Eisai Aduhelm experience shows, CMS can on occasion have a profound impact on product launches when it chooses to.

Destiny Pharma's XF-73 achieved an "exceptionally high" 99.5% reduction in Staphylococcus aureus bacterial nasal carriage in a mid-stage trial, a result that should attract a number of potential partners for the UK firm.

BTIG analyst expects SeaSpine’s acquisition of 7D Systems will help SeaSpine morph into a procedurally integrated solutions provider.

Executives share their expectations and hopes around the multi-faceted topic of patient access to medicines. From health inequities to value assessment and reimbursement trends, expectations for change abound.